FDA Matters logo
  • Blog
  • About
  • Media
What I Learned By Speaking About “FDA in Trump 2.0”

What I Learned By Speaking About “FDA in Trump 2.0”

by Steven Grossman | Mar 12, 2025 | Short Takes and Updates

If you have not signed up to receive the FDA Matters newsletter in your email box, go to the home page to sign up. On Monday, I had the honor to address the annual meeting of America’s Blood Centers (ABC). It reminded me how much I learn by preparing for speeches and...
What I Learned By Speaking About “FDA in Trump 2.0”

Short Takes and Updates—March 7 2025

by Steven Grossman | Mar 7, 2025 | Short Takes and Updates

If you have not signed up to receive the FDA Matters newsletter in your email box, go to the home page to sign up. 1. Taken From This Week’s Headlines Elon Musk learns there is a Budget Control Act protocol, known as recissions, for cutting appropriated funding....
What I Learned By Speaking About “FDA in Trump 2.0”

Lessons from Dr. Gottlieb’s 2017 Confirmation Hearing

by Steven Grossman | Mar 4, 2025 | Short Takes and Updates

If you have not signed up to receive the FDA Matters newsletter in your email box, go to the home page to sign up. President Trump nominated Johns Hopkin Professor Martin Makary to be the next Commissioner of FDA. His confirmation hearing is Thursday, March 6 at 10...
What I Learned By Speaking About “FDA in Trump 2.0”

Fresh Thinking: Extending Healthy Lifespans

by Steven Grossman | Feb 27, 2025 | Short Takes and Updates

LIVE EVENT!Come join us tomorrow, (Friday, February 28) at 11 a.m. ET to discuss the need for a regulatory pathway to enable the development of products that extend the span of life free of chronic diseases and...
What I Learned By Speaking About “FDA in Trump 2.0”

Short Takes and Updates—February 25, 2025

by Steven Grossman | Feb 25, 2025 | Short Takes and Updates

If you have not signed up to receive the FDA Matters newsletter in your email box, go to the home page to sign up. 1. Never Lose the Whip CountToday (or this week’s) House vote on the reconciliation budget is likely to be one of the most momentous votes in my lifetime...
What I Learned By Speaking About “FDA in Trump 2.0”

SPECIAL EDITION: FDA, Lay-offs, and User Fees Explained

by Steven Grossman | Feb 23, 2025 | Short Takes and Updates

Information for Reporters[1] Note: Since the original column was published, I have become aware that lay-offs should not be referred to as a reduction-in-force (RIF) because that term triggers certain procedures and protections that employees might not have in the...
« Older Entries
Next Entries »

Recent Posts

  • Chairman Cassidy: Please Ask Dr. Overton About FDA Decision-Making
  • The FDA’s Century-Long Campaign to Assure Safe Manufacturing (Part 2)
  • The FDA’s Century-Long Campaign to Assure Safe Drug Manufacturing (Part 1)
  • A Marathon, Not a Sprint: The Long Road to Becoming the Next FDA Commissioner
  • Firing Dr. Makary Solves No Problems….BUT Opens the Door for More Orderly Management and Decision-Making

Recent Comments

No comments to show.
FDA Matters logo

 ©2009-2026 FDA Matters | FDA Matters does not report the news….we provide analysis of what’s behind the news.

We sometimes use artificial intelligence in drafting columns, primarily using Claude AI and Microsoft Co-Pilot. We review and verify all findings, interpretations, and final wording.